These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 33909703)

  • 1. Correction: PCC0208025 (BMS202), a small molecule inhibitor of PD-L1, produces an antitumor effect in B16-F10 melanoma-bearing mice.
    PLOS ONE Staff
    PLoS One; 2021; 16(4):e0251020. PubMed ID: 33909703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PCC0208025 (BMS202), a small molecule inhibitor of PD-L1, produces an antitumor effect in B16-F10 melanoma-bearing mice.
    Hu Z; Yu P; Du G; Wang W; Zhu H; Li N; Zhao H; Dong Z; Ye L; Tian J
    PLoS One; 2020; 15(3):e0228339. PubMed ID: 32214351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined SEP and anti-PD-L1 antibody produces a synergistic antitumor effect in B16-F10 melanoma-bearing mice.
    Hu Z; Ye L; Xing Y; Hu J; Xi T
    Sci Rep; 2018 Jan; 8(1):217. PubMed ID: 29317734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel Treatment of Melanoma: Combined Parasite-Derived Peptide GK-1 and Anti-Programmed Death Ligand 1 Therapy.
    Vera-Aguilera J; Perez-Torres A; Beltran D; Villanueva-Ramos C; Wachtel M; Moreno-Aguilera E; Vera-Aguilera C; Ventolini G; Martínez-Zaguilán R; Sennoune SR
    Cancer Biother Radiopharm; 2017 Mar; 32(2):49-56. PubMed ID: 28301259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemoradiation Increases PD-L1 Expression in Certain Melanoma and Glioblastoma Cells.
    Derer A; Spiljar M; Bäumler M; Hecht M; Fietkau R; Frey B; Gaipl US
    Front Immunol; 2016; 7():610. PubMed ID: 28066420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of [
    Vermeulen K; Naus E; Ahamed M; Attili B; Siemons M; Luyten K; Celen S; Schymkowitz J; Rousseau F; Bormans G
    Theranostics; 2019; 9(2):554-572. PubMed ID: 30809293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancing CTL responses to melanoma cell vaccines in vivo: synergistic increases obtained using IFNgamma primed and IFNbeta treated B7-1+ B16-F10 melanoma cells.
    Dezfouli S; Hatzinisiriou I; Ralph SJ
    Immunol Cell Biol; 2003 Dec; 81(6):459-71. PubMed ID: 14636243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of [
    Vermeulen K; Ahamed M; Luyten K; Bormans G
    Nucl Med Biol; 2019; 74-75():1-11. PubMed ID: 31421440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IL-12 plasmid delivery by in vivo electroporation for the successful treatment of established subcutaneous B16.F10 melanoma.
    Lucas ML; Heller L; Coppola D; Heller R
    Mol Ther; 2002 Jun; 5(6):668-75. PubMed ID: 12027550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of DL-alpha-difluoromethylornithine on the growth and metastasis of B16 melanoma in vivo.
    Kubota S; Ohsawa N; Takaku F
    Int J Cancer; 1987 Feb; 39(2):244-7. PubMed ID: 3100460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prim-O-glucosylcimifugin enhances the antitumour effect of PD-1 inhibition by targeting myeloid-derived suppressor cells.
    Gao W; Zhang X; Yang W; Dou D; Zhang H; Tang Y; Zhong W; Meng J; Bai Y; Liu Y; Yang L; Chen S; Liu H; Yang C; Sun T
    J Immunother Cancer; 2019 Aug; 7(1):231. PubMed ID: 31462297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thymoquinone Enhances the Effect of Gamma Knife in B16-F10 Melanoma Through Inhibition of Phosphorylated STAT3.
    Hatiboglu MA; Kocyigit A; Guler EM; Akdur K; Khan I; Nalli A; Karatas E; Tuzgen S
    World Neurosurg; 2019 Aug; 128():e570-e581. PubMed ID: 31054338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous administration of bone marrow-derived multipotent mesenchymal stromal cells enhances the recruitment of CD11b(+) myeloid cells to the lungs and facilitates B16-F10 melanoma colonization.
    Souza LE; Almeida DC; Yaochite JN; Covas DT; Fontes AM
    Exp Cell Res; 2016 Jul; 345(2):141-9. PubMed ID: 26027946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Migration and invasion in B16-F10 mouse melanoma cells are regulated by Nrf2 inhibition during treatment with ionizing radiation.
    Gao Y; Zhao Z; Meng X; Chen H; Fu G
    Oncol Lett; 2018 Aug; 16(2):1959-1966. PubMed ID: 30008889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppression of B16 melanoma lung colonization by syngeneic monoclonal antibodies.
    Herd ZL
    Cancer Res; 1987 May; 47(10):2696-703. PubMed ID: 3552203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Forsythiae Fructus Inhibits B16 Melanoma Growth Involving MAPKs/Nrf2/HO-1 Mediated Anti-Oxidation and Anti-Inflammation.
    Bao J; Ding R; Zou L; Zhang C; Wang K; Liu F; Li P; Chen M; Wan JB; Su H; Wang Y; He C
    Am J Chin Med; 2016; 44(5):1043-61. PubMed ID: 27430915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Inhibitory effect of tripeptide compound tyroservaltide on invasion and metastasis of mouse melanoma cell line B16-F10].
    Che XC; Lu R; Hu JX; Zheng MN; Zhang MF; Wang S; Yu CY; Yang XL; Xing DH; Yao Z
    Ai Zheng; 2006 Mar; 25(3):275-80. PubMed ID: 16536978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Melanoma-Targeting Property of Y-90-Labeled Lactam-Cyclized α-Melanocyte-Stimulating Hormone Peptide.
    Xu J; Yang J; Gonzalez R; Fisher DR; Miao Y
    Cancer Biother Radiopharm; 2019 Nov; 34(9):597-603. PubMed ID: 31644317
    [No Abstract]   [Full Text] [Related]  

  • 19. Correction: BNIP3 modulates the interface between B16-F10 melanoma cells and immune cells.
    Romano E; Rufo N; Korf H; Mathieu C; Garg AD; Agostinis P
    Oncotarget; 2018 Dec; 9(97):37076. PubMed ID: 30651937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced tumorigenicity of B16-F10 mouse melanoma cells transfected with mycobacterial antigen 85A.
    Tarrant JP; Walsh MJ; Blanchard MC; Lee TD; Hoskin DW; Giacomantonio CA
    Int J Oncol; 2004 Dec; 25(6):1693-9. PubMed ID: 15547707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.